Introduction
============

Since the launch in 2003 of the Alzheimer's Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. At the core of its conception, the ADNI is a multicenter and multidisciplinary approach for the study and longitudinal characterization of the natural history of aging and Alzheimer's disease (AD) by means of structural and functional neuroimaging and fluid biomarkers along with clinical evaluations and neuropsychological assessments. Over the years, the aims and scope of the ADNI were expanded and refined, always aiming at increasing our understanding of the pathogenesis of AD -- knowledge that can be now translated into more accurate and sensitive diagnostic and prognostic tests and techniques to guide therapeutic interventions by predicting and/or by monitoring response to therapy.

The ADNI proposed a novel and unique way of doing business. From the very beginning, data obtained by the study have been freely shared without embargo with the scientific community. For that purpose, data from the respective streams were centralized to ensure quality, and were made available to any registered researcher around the world. This sharing allows validation of results, as well as the identification of the most relevant and sensitive parameters at each stage of the disease that can be then translated into the design of therapeutic trials. This sharing also allows probing, challenging and comparing techniques for their diagnostic, prognostic and/or theragnostic value, testing new approaches, exploring new avenues and postulating new questions. This is perfectly illustrated by a case in which the same North American Alzheimer's Disease Neuroimaging Initiative (NA-ADNI) magnetic resonance imaging (MRI) dataset yielded different longitudinal estimates of brain atrophy due to a methodological bias \[[@B1]\],\[[@B2]\], and how this bias was corrected \[[@B3]\]. While a series of steps were proposed to avoid similar issues in the future \[[@B4]\], this case underscored the need for a gold standard and highlighted how such a gold standard might need to be redefined under the new light of biomarkers \[[@B4]\],\[[@B5]\].

These issues have not discouraged researchers around the world, and they have been steadily and increasingly accessing and downloading ADNI data. The latest available reports show that ADNI data were accessed from more than 35 countries worldwide, by researchers at academic and governmental institutions, as well as by those in pharmaceutical and biotechnology industries \[[@B6]\],\[[@B7]\]. Furthermore, the ADNI in collaboration with the Alzheimer's Association has put in motion international efforts for the standardization of biomarkers in order to increase compatibility between different centers.

In response to the initial NA-ADNI, several similar initiatives for the study of AD were put in place in Australia (Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging (AIBL)), Japan (Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI)) and Europe (European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)). China, South Korea, Taiwan and Argentina have recently started recruiting participants, while other countries, such as Brazil and India, are at the planning stages of setting up like-minded consortia (Figure [1](#F1){ref-type="fig"}). This international approach will provide a multifaceted view of AD, finding the commonalities and differences across ethnicities and cultures, allowing cross-pollination and promotion of ideas, refinement of techniques, and improved assistance that can directly and/or indirectly affect the care, and potentially the cure, of this devastating disease. Furthermore, based on the ADNI model, imaging initiatives were organized around other neurodegenerative conditions such as the Parkinson Progression Marker Initiative \[[@B8]\].

![**World Wide Alzheimer's Disease Neuroimaging Initiative*.*** Map of established (North America, Europe, Australia and Japan), recently started (Argentina, China, Korea and Taiwan), and projected (Brazil & India) Alzheimer's Disease Neuroimaging Initiative (ADNI) sites. A-ADNI, Argentina Alzheimer's Disease Neuroimaging Initiative; AIBL, Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging (Australian Alzheimer's Disease Neuroimaging Initiative); C-ADNI, China Alzheimer's Disease Neuroimaging Initiative; E-ADNI, European Alzheimer's Disease Neuroimaging Initiative; J-ADNI, Japan Alzheimer's Disease Neuroimaging Initiative; K-ADNI, Korea Alzheimer's Disease Neuroimaging Initiative; NA-ADNI, North American Alzheimer's Disease Neuroimaging Initiative; T-ADNI, Taiwan Alzheimer's Disease Neuroimaging Initiative.](s13195-014-0062-5-1){#F1}

We shall present an overview of each of these initiatives, trying to highlight their similarities and dissimilarities, accomplishments and pending issues. From the outset we know this is a Herculean task, and that much will be overlooked. The omissions will be more a reflection of the reviewers' limitations than the initiatives they attempt to review.

Established Alzheimer's Disease Neuroimaging Initiative consortia
=================================================================

North American Alzheimer's Disease Neuroimaging Initiative
----------------------------------------------------------

Since its inception in 2003, the NA-ADNI has focused on structural neuroimaging and fluid biomarkers for AD \[[@B9]\], assessing their validity as both surrogate markers for treatment trials and as a way to reduce trial cost and speed up drug development \[[@B10]\]. The ADNI was constituted as a public (National Institute on Aging, National Institute of Mental Health, National Institute of Biomedical Imaging and Bioengineering, National Institute for Alcohol Abuse and Alcoholism and the US Food and Drug Administration)--private (pharmaceutical companies along with private nonprofit philanthropic organizations, such as the Alzheimer's Drug Discovery Foundation, Foundation of the National Institutes of Health and Alzheimer's Association) collaboration, combining forces and sharing resources, infrastructure and information from diverse groups of academia, industry, nonprofit organizations and government in order to provide the foundation for the testing of new therapeutic approaches while at the same time speeding their development.

The initial phase of the NA-ADNI (ADNI 1) assessed more than 800 participants from about 60 centers in the USA and Canada. ADNI 1 was divided into five different cores: a neuroimaging core that included MRI \[[@B11]\] and fluorodeoxyglucose (FDG) positron emission tomography (PET); a clinical core that included the neuropsychological assessments; a biomarker core primarily focused on cerebrospinal fluid (CSF) and plasma analytes; a statistics core; and an informatics core. This initial phase included longitudinal assessments of cognition, MRI and blood in older cognitively unimpaired individuals, subjects classified as having mild cognitive impairment (MCI) and AD patients. About one-half of them also underwent lumbar puncture and/or FDG PET studies \[[@B12]\], and about 100 participants had amyloid-beta (Aβ) imaging with ^11^C-Pittsburgh Compound B (PiB) PET. To better characterize the prodromal stage of AD, a second phase of ADNI (ADNI-GO) incorporated individuals in the early stages of MCI \[[@B13]\]. The latest round of funding supported ADNI 2, which recruited \~700 new participants to the longitudinal study that, counting those participants retained from ADNI 1 and ADNI-GO, constitutes a cohort of about 1,100 participants.

Since its inception there has been a steady output of publications from the different cores of the NA-ADNI \[[@B7]\]. The tight collaboration of the different cores has already allowed integration of data, increasing the predictive power of the different markers along the spectrum of the disease but also to order them in time, with Aβ markers becoming abnormal first followed by changes in markers of neurodegeneration \[[@B14]\]. The clinical core, the cornerstone of all the other streams, has been refining and redefining the classifications of the different phases of the disease, trying to better characterize the early stages of the AD spectrum, evaluating not only their diagnostic performance but also their predictive power \[[@B15]\],\[[@B16]\]. The biomarkers core has focused on fluid biomarkers trying to better characterize the known AD profile in CSF \[[@B17]\],\[[@B18]\], but also searching for a plasma biomarker(s) profile that could predict disease progression especially at the predementia stages of the disease \[[@B14]\],\[[@B19]\]. Furthermore, longitudinal CSF data from NA-ADNI has made it possible to trace the dynamic changes in CSF Aβ, T-tau and p-tau over time, showing that Aβ becomes abnormal about 16 years before the onset of AD dementia \[[@B20]\]. The formation of the NA-ADNI and similar consortia allowed the combination of samples of multiple sites allowing new genome-wide association studies, which not only confirmed the relevance of certain gene candidates such as CLU and PICALM \[[@B21]\] but also revealed novel gene candidates and biological pathways \[[@B22]\].

The structural neuroimaging core has successfully standardized image acquisition and image processing and analysis protocols across multiple MRI scanners and across different MRI field strengths \[[@B11]\],\[[@B23]\], maintaining methodological consistency throughout the different stages of the NA-ADNI \[[@B24]\]. Protocols have been updated and all new enrollments undergo a 3T MRI and a core set of three sequences: a T1 magnetization-prepared rapid acquisition with gradient echo for brain volumetrics; fluid attenuated inversion recovery for the detection and quantification of white matter hyperintensities; and gradient echo MRI for the detection of microhemorrhages. Some centers also add new sequences such as arterial spin labeling for the quantification of brain perfusion, resting-state functional MRI to assess brain connectivity and diffusion tensor imaging for tractography mapping \[[@B24]\]. The PET core started by focusing on glucose metabolism and how to standardize studies acquired across multiple sites \[[@B12]\],\[[@B25]\],\[[@B26]\], standardization that has not only confirmed previous FDG findings \[[@B25]\],\[[@B27]\] but has also provided new insights through novel analytical paradigms \[[@B26]\],\[[@B28]\],\[[@B29]\]. The PET core was expanded to include Aβ imaging, initially with ^11^C-PiB \[[@B30]\] and then with ^18^F-florbetapir \[[@B31]\],\[[@B32]\]. More than 1,000 NA-ADNI participants have undergone ^18^F-florbetapir imaging.

The establishment of the NA-ADNI with its particular *weltanschauung* set in motion similar consortia around the world imbued of the same spirit, a movement that is gaining momentum and adherents; a movement that will provide an extraordinary wealth of data for the scientific world to share, dissect and examine for years to come.

European Alzheimer's Disease Neuroimaging Initiative
----------------------------------------------------

Founded in 2005, initially the E-ADNI was a pilot project funded by the Alzheimer\'s Association \[[@B33]\] in order to evaluate how many sites from a network of more than 50 clinical and research centers already participating in the European Alzheimer\'s Disease Consortium had the expertise, willingness and infrastructure to adopt the NA-ADNI structure and protocols \[[@B34]\]. The pilot study demonstrated not only that the selected centers were able to recruit healthy older volunteers as well as MCI and AD subjects, but that the clinical, imaging and biological data collected were equivalent to those from the NA-ADNI \[[@B34]\]. This pilot study led the European Commission to financially support the development of neuGRID in 2008 and neuroGRID4U later on \[[@B35]\].

One of the differences between the E-ADNI and the NA-ADNI was the inclusion of nonamnestic MCI as well as cases with subcortical vascular cognitive impairment and dementia. This approach allowed a wider assessment of different underlying etiologies of dementia, resulting in a more comprehensive look at aging.

The NA-ADNI and the E-ADNI had also joined forces in an effort to standardize and harmonize the landmarks and basic image analysis procedures for the segmentation of the hippocampus, measurement that can be used reliably and consistently across clinical settings and could eventually be useful as a surrogate marker for drug trials \[[@B36]\],\[[@B37]\]. A similar effort has concentrated on reaching a consensus for assessing FDG-PET data in a standardized unbiased way \[[@B38]\].

The collaboration between different European centers helped increase understanding of the clinical and predictive nature of Aβ imaging \[[@B39]\], and also helped to develop a predictive model combining information from MRI, FDG and CSF Aβ \[[@B40]\].

The efforts of the E-ADNI were not only concentrated in neuroimaging but also in fluid biomarkers, using the pilot data to validate and standardize results from across six different centers \[[@B41]\]. The integration of procedures and datasets of the ADNI with AddNeuroMed, a private--public consortium looking at the discovery of novel peripheral biomarkers, led to the identification and validation of markers such as α~2~-macroglobulin and complement factor C3 that are elevated in AD \[[@B42]\] and also of how plasma proteins correlated with markers of neurodegeneration \[[@B43]\] or cytokines combined with brain atrophy can be used as predictive markers of disease progression \[[@B44]\]. Further collaboration compared the diagnostic and predictive accuracy of several rating approaches for mesial temporal atrophy \[[@B45]\]-\[[@B47]\].

Australian Alzheimer's Disease Neuroimaging Initiative
------------------------------------------------------

The Australian ADNI, better known as the AIBL \[[@B48]\], was launched in 2006 as a prospective study of more than 1,000 older individuals \[[@B49]\],\[[@B50]\]. One of the distinctive features of AIBL was the inclusion of a large proportion (\~70%) of healthy older individuals who, along with MCI (12%) and AD subjects (20%), were followed-up every 18 months, collecting data on demographic, genetic and lifestyle factors, cognitive function and fluid biomarkers. About one-third of the participants underwent structural MRI and Aβ imaging scans with PiB PET \[[@B50]\],\[[@B51]\]. While the AIBL adopted a very similar approach to neuropsychological assessments, blood biomarkers and structural MRI, the approach to disease-specific biomarkers differed -- the AIBL concentrated from the very beginning on Aβ imaging, while the NA-ADNI initially focused on FDG and CSF biomarkers.

Another particular feature of the AIBL is the inclusion of a dedicated lifestyle research stream assessing the effects of exercise and/or dietary modifications on cognition or biomarkers, which showed that higher intensity exercise was associated with better cognitive function in older controls \[[@B52]\]. In the area of fluid biomarkers, lower plasma Aβ~1--42~/Aβ~1--40~ ratio was associated with disease progression in controls and with brain Aβ in MCI and AD cases \[[@B53]\]. Also, AD patients had significantly lower total plasma apolipoprotein E (ApoE) levels than controls or MCI patients \[[@B54]\], but higher luteinizing hormone in serum \[[@B55]\]. A perfect example of the cross-validation afforded by sharing databases is an AIBL study where a panel of biomarkers predicting brain Aβ burden with a sensitivity and specificity of 80% and 82%, respectively, were further validated using independent biomarker data from the NA-ADNI \[[@B56]\].

Initial neuroimaging results showed that the prevalence of high Aβ burden (Aβ+) in cognitively unimpaired individuals increased with age, and was higher in individuals carrying at least one APOE ε4 allele \[[@B51]\]. Furthermore, the Aβ burden was related to worse cognitive performance in cognitively unimpaired females, raising questions with regard to gender susceptibility to Aβ \[[@B57]\]. While memory in the cognitively unimpaired adults with low Aβ burden (Aβ--) remained stable over 18 months, all aspects of episodic memory were observed to deteriorate substantially in Aβ + nondemented participants \[[@B58]\],\[[@B59]\].

From a clinical perspective, some biomarkers have been shown to serve as predictors of disease progression. For example, Aβ imaging data demonstrated that Aβ + amnestic MCI cases were much more likely to progress to AD over 18 to 36 months than Aβ-- MCI cases \[[@B60]\],\[[@B61]\]. Subtle memory impairment in Aβ + healthy individuals indicated that these individuals were at high risk to progress to MCI or AD within 3 years \[[@B61]\]. Aβ deposition was also found to be strongly related to grey matter atrophy, where the rates of grey matter atrophy were significantly higher in Aβ + cognitively unimpaired individuals \[[@B62]\],\[[@B63]\]. Moreover, the hippocampal volume and temporal Aβ deposition provided independent contributions to memory deficits, suggesting that both factors should be independently targeted in therapeutic trials aimed at reducing cognitive decline \[[@B64]\]. These associations were not observed at the MCI and AD stages, suggesting that other pathological, probably downstream, events might be responsible for the progressive atrophy and cognitive decline \[[@B65]\]. When assessing whether brain-derived neurotrophic factor polymorphism moderated the relationship between cognition, brain volume and Aβ burden in cognitively unimpaired individuals, carrying a Met allele was associated with moderate decline in episodic memory, reductions in hippocampal volume and increased risk of progression to MCI when compared with Val/Val homozygotes \[[@B66]\], but that it did not affect rates of Aβ accumulation \[[@B66]\].

The prospective longitudinal design of the study allowed the examination of changes in Aβ burden over time, where small but significant increases in neocortical Aβ burden were observed in the AD and MCI groups, and in Aβ + controls, confirming the notion that Aβ deposition precedes cognitive impairment \[[@B60]\]. Furthermore, higher rates of Aβ deposition were associated with higher Aβ burden and identified the existence of Aβ accumulators and Aβ nonaccumulators, with Aβ accumulators even found among Aβ-- controls \[[@B67]\]. Consequently, Aβ imaging data from the 3-year follow-up were then used to calculate the rates of Aβ deposition over time, showing that Aβ deposition is a slow and protracted process that takes about two decades to go from the threshold of abnormal Aβ burden to the levels usually observed in AD \[[@B68]\] and that Aβ deposition precedes by more than a decade hippocampal atrophy and memory impairment \[[@B68]\].

Renovated efforts are aimed at obtaining structural and Aβ imaging on all participants enrolled in the study. To date, the AIBL has enrolled almost an additional 600 individuals undergoing longitudinal Aβ imaging studies either with ^11^C-PiB (*n* = 65), ^18^F-flutemetamol (*n* = 204), ^18^F-florbetaben (*n* = 127) or ^18^F-florbetapir (*n* = 195).

Japanese Alzheimer's Disease Neuroimaging Initiative
----------------------------------------------------

Discussions for the launch of the J-ADNI \[[@B69]\] started in 2006, as a result of the urgent need to meet the requirements for global clinical trials of AD disease-modifying drugs that were about to start in Japan. Japanese neurologists, psychiatrists, geriatricians and neuroradiologists, despite their high scientific performance in dementia, had little experience in nationwide or global-level clinical studies of AD \[[@B70]\],\[[@B71]\]. Second, Japan did not have sufficient infrastructures, such as the Alzheimer's Disease Cooperative Study, that are required to conduct clinical studies or trials of AD. Therefore, in 2007 the J-ADNI was funded by the two major governmental funding agencies: the Ministry of Health, Labor and Welfare; and the New Energy and Industrial Technology Development Organization (a foundation of the Ministry of Economy, Technology, and Industry) \[[@B70]\],\[[@B71]\]. Seven domestic pharmas (Astellas, Eisai, Daiichi-Sankyo, Dainippon-Sumitomo, Shionogi, Takeda, Tanabe-Mitsubishi) and four international pharmas (Bristol-Myers Squibb, Eli-Lilly, Merck-Banyu, Pfizer) organized an industry scientific advisory board and contributed one-third of the total 500,000,000¥/year J-ADNI budget.

The J-ADNI research protocol was designed to maximize compatibility with the NA-ADNI, including structural MRI, FDG and Aβ imaging with PET, CSF sampling and APOE genotyping, combined with a set of clinical and psychometric tests. The initially planned sample size for the study was 300 individuals with amnestic MCI, 150 early AD individuals and 150 cognitively normal individuals. In total, 38 clinical sites participated in the J-ADNI. The clinical core ensures that the registration and clinical evaluation of the participants closely collaborates with the neuropsychology core, the latter being responsible for maximizing the harmonization between English and Japanese versions of psychometric tests. The MRI core has established an algorithm to achieve the standardization of MRI scans among clinical sites using different MRI scanners from various vendors, based on a three-dimensional magnetization-prepared rapid acquisition with gradient echo scan protocol using the ADNI phantom. Researchers at the J-ADNI have created programs for the correction and calibration of signal equity or distortion of the images, which enabled the rigorous volumetric analysis of MRI data \[[@B72]\]. The PET core has established the standardized protocol for PET imaging in the J-ADNI. Twenty-eight sites are conducting FDG PET, covering \~67% of participants, and analysis of the multicenter data has started \[[@B73]\]-\[[@B75]\]. Aβ imaging using ^11^C-PiB started in \~15 sites, with two sites also performing Aβ imaging studies using ^11^C-BF-227. About 40% of the J-ADNI cohort had undergone Aβ imaging. The biomarker core established the J-ADNI biosample repository in Niigata University, centralizing the nationwide collection network of biofluid samples. Blood samples are collected from all participants at every visit, and \~40% of the participants had lumbar puncture for CSF samples without severe adverse events. The biomarker core has recently achieved the harmonization of protocol for X-MAP quantitation of CSF samples using Alzbio3 enzyme-linked immunosorbent assay, in collaboration with NA-ADNI biomarker core and Innogenetics. The APOE genotype is also characterized at the Niigata site.

By spring 2012 the 38 clinical sites had enrolled 545 participants meeting the inclusion criteria (239 amnestic MCI individuals, 154 cognitively normal older individuals, and 152 early AD individuals). More than 3,600 visits (that comprise \~97% of the total scheduled visits) were completed by autumn 2013, and all data continue to be analyzed, with analysis to be completed by mid 2014. Briefly, the conversion rate of late amnestic MCI individuals appears to be slightly higher than those in the NA-ADNI, at similar levels to those of the late amnestic MCI cases from the National Alzheimer's Coordinating Center, USA, with Aβ-positive MCI individuals exhibiting higher rates of conversion to dementia. The rates of hippocampal atrophy were comparable with those measured in the NA-ADNI and, as in the NA-ADNI, lower Aβ~1--42~ in CSF was in good accordance with Aβ + PET scans.

Currently, the second phase of the J-ADNI (J-ADNI2) is being launched, focusing on the two populations of older individuals with very early stages of AD; that is, preclinical AD and early/late amnestic MCI. The first participant was screened on 11 December 2013. J-ADNI2 is comprised of two studies. The first is aimed at preclinical AD, where \~700 cognitively normal older individuals will undergo Aβ imaging at 31 PET sites with one of several probes, either ^11^C-PiB, ^18^F-florbetapir or ^18^F-flutemetamol. The scans will allow selection and recruitment of 150 cognitively normal, Aβ + individuals meeting the criteria of preclinical AD that will be followed-up in an annual fashion for 3 years. The second study of J-ADNI2 is the MCI study, devoted to the longitudinal investigation of early and late amnestic MCI, according to the criteria used by the NA-ADNI2. CSF sampling and Aβ imaging, together with structural MRI using 3T scanners and either of the three optional sequences (resting-state functional MRI, arterial spin labeling, or diffusion tensor imaging) will be performed in all participants of preclinical AD and MCI studies. These studies will pave the way towards the upcoming clinical trials of prodromal AD (or MCI due to AD) and the future very early treatment of preclinical AD in Japan, similar to the A4 anti-Aβ treatment of asymptomatic AD in the USA.

More recent Alzheimer's Disease Neuroimaging Initiative consortia
=================================================================

Argentina, China, Korea and Taiwan have recently joined the World Wide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI)-like efforts in the study of AD. Another two countries are establishing the platforms to launch their respective studies. With arrangements already in place, Brazil plans to join the WW-ADNI in 2014 -- aiming at the study of healthy older controls, individuals reporting subjective memory complaints, MCI and AD patients -- while India is trying to secure funding for their planned 5-year prospective study.

Argentina Alzheimer's Disease Neuroimaging Initiative
-----------------------------------------------------

After institutional review board approval in 2011, the Argentina Alzheimer's Disease Neuroimaging Initiative has already recruited 60 participants, with plans to expand the cohort to 300 participants. To date, most participants have undergone CSF and blood examination, MRI, FDG and PiB scans. A unique characteristic of the Argentina Alzheimer's Disease Neuroimaging Initiative is the intention to use the same methodological approach to study the adult offspring of AD patients that present with autonomic and circadian abnormalities. The results from the initial CSF assessments were presented in Boston in 2013 \[[@B76]\].

China Alzheimer's Disease Neuroimaging Initiative
-------------------------------------------------

The China Alzheimer's Disease Neuroimaging Initiative is planned as a 5-year prospective study aiming at recruiting 800 to 1,000 participants in the first 2 years, with an emphasis on MCI subjects. Clinical and neuropsychological evaluation will be performed every 6 months, with fluid biomarkers and neuroimaging every year. After fluid biomarker, MRI and FDG protocols were established and implemented, recruitment started in 2012. Aβ imaging with ^18^F-florbetapir is planned to commence in 2014. At the last WW-ADNI update in Boston in 2013, 16 subjects had already been enrolled, with 11 of them having completed a 1-year follow-up \[[@B77]\].

Korea Alzheimer's Disease Neuroimaging Initiative
-------------------------------------------------

The Korea Alzheimer's Disease Neuroimaging Initiative is a project funded by both industry and the Korean Ministry of Health and Welfare. This 6-year project aims at recruiting 500 participants for the initial 2 years, and then following them up annually. A distinctive and important feature of the Korea Alzheimer's Disease Neuroimaging Initiative is that it will enroll in the study, in a more vigorous way than the E-ADNI, individuals with either vascular MCI or subcortical vascular dementia. Twenty-five nationwide clinical sites will recruit and monitor the progress of 50 healthy controls, 200 MCI individuals, 100 vascular MCI individuals, 50 AD individuals and 100 subcortical vascular dementia subjects. As with the other ADNI initiatives, participants will be characterized and followed-up with cognitive tests, fluid (including blood, CSF and ApoE genotype) and neuroimaging (MRI, FDG and Aβ imaging with ^18^F-flutemetamol) biomarkers. Given the relatively large proportion of Asian patients affected by vascular dementia and continuing an already established line of investigation \[[@B78]\], the Korea Alzheimer's Disease Neuroimaging Initiative plans to evaluate the effects of vascular risk factors on the development and progression of AD and subcortical vascular dementia. At the WW-ADNI meeting in Boston in 2013 \[[@B77]\], the Korea Alzheimer's Disease Neuroimaging Initiative reported to be in the final stages of setting up the infrastructure for the study and ready to start recruiting early in 2014.

Taiwan Alzheimer's Disease Neuroimaging Initiative
--------------------------------------------------

The Taiwan Alzheimer's Disease Neuroimaging Initiative plans to enroll 200 older individuals following the same criteria as ADNI-GO that, besides enrolling a group of AD patients and a group of age-matched healthy controls, separates the MCI subjects into early or late MCI. The initial phase of the study will involve six centers, eventually expanding to a total of 12 centers across Taiwan. Participants will undergo cognitive tests and testing for fluid biomarkers. Neuroimaging will comprise extensive three-dimensional MRI (volumetry, diffusion tensor imaging, resting-state functional MRI, susceptibility weighted imaging and magnetic resonance spectroscopy) as well as FDG and building on their previous Aβ imaging experience with ^18^F-florbetapir \[[@B79]\]-\[[@B81]\].

Limitations
===========

The limitations of the ADNI model are often acknowledged by ADNI researchers \[[@B7]\]. Some of these limitations are related to the study design, some of them are related to data collection, storage and analysis, and some are related to the potential misuse of the shared data. The study was designed as an observational, natural progression study, not as a clinical trial, so while it might identify relevant biomarkers and establish their behavior over time, it cannot predict how or how much those biomarkers will change in response to therapy. Another limitation is that the study uses sharply defined clinical groups in a specific age range, with a particular emphasis on memory impairment that might preclude the generalization of the findings to the general population; therefore, the study is not ideal to test the diagnostic properties of some biomarkers. Other studies, evaluating a large sample of individuals from the general population with a wide variety of comorbidities, will be required to assess the real impact of the contributions of the ADNI.

Another set of limitations are related to data collection, including how and when biological samples are collected, stored and analyzed \[[@B82]\], image quality across time and across centers, as well as what is not being collected or what other techniques are not being used \[[@B7]\]. For example, not all tests are administered to all participants. Within the same cohort this is illustrated by the fact that not all NA-ADNI participants undergoing CSF examination had FDG scans, and across cohorts by the fact that, while participants from the NA-ADNI had both FDG and CSF collected, these tests were not performed in the AIBL cohort. Another issue is missing data due to attrition (for example, death, dropout, or withdrawal) as well as some data that had to be discarded due to poor quality.

Finally, another issue that has been raised against ADNI results is that these results are mainly confirmatory. While the argument is valid in some cases, what is overlooked is that the confirmation, as well as the refutation, of the usefulness of certain biomarkers was performed in a large cohort of individuals, in contrast with the smaller samples used in the original evaluations. Not only that, the longitudinal design of the study also allows for the assessment of the change of those biomarkers over time. This cross-sectional and longitudinal validation of biomarkers in a large cohort is a necessary step in order to translate these biomarkers into clinical practice.

Conclusions
===========

The prospective and multidisciplinary approach adopted by the ADNI has made substantial contributions to the understanding of cognitive and physiological changes associated with aging in general, and the AD spectrum in particular. Furthermore, the identification and validation in a large cohort of specific biomarkers provides a framework to assess AD risk in individuals prior to the onset of the clinical phenotype, while eventually allowing evaluation of the therapeutic and lifestyle interventions likely to emerge within the next decade aimed at preventing or delaying the onset of symptoms. Data gathered from different ADNI sites concurred in showing that some of the pathological changes characteristic of the disease are already present at the preclinical and prodromal stages, eventually leading to the postulation of new diagnostic criteria based on markers of pathology (Aβ) and markers of neuronal injury \[[@B83]\]-\[[@B85]\]. The implementation of the new staging criteria for preclinical AD \[[@B84]\] in an independent cohort showed that about 25% of the cases presented with AD-like neurodegeneration but no significant Aβ deposition, leading to the introduction of an additional category labeled 'suspected non-Alzheimer's disease pathology' \[[@B86]\]. Some of these biomarkers have also been used to predict the rate of evolution of the preclinical changes and the onset of the clinical phase of AD, crucial for the design and timing of disease-specific interventions. For example, CSF \[[@B20]\],\[[@B68]\] and Aβ imaging studies \[[@B20]\],\[[@B68]\] have shown that extensive Aβ deposition precedes significant cognitive impairment by more than 15 to 20 years, results that were further validated in a different cohort \[[@B87]\]. One issue to be highlighted is that these estimates of a process that probably extends decades were derived from still relatively short longitudinal assessments. Longer follow-ups will be required to reassess and revise the current results \[[@B20]\],\[[@B68]\],\[[@B87]\].

We are still not aware of the full impact of the ADNI. Only time will be able to judge the enormous contribution, founding blueprint, and insightful roadmap that the ADNI provided to the study of AD. What we do know is that the ADNI way of doing business, sharing data and joining efforts, setting standards and fostering collaborations, multimodal approaches and international cooperation are already among its most remarkable accomplishments, and that these interactions and cross-pollination inform, reform and transform ongoing and newly developed research protocols, while at the same time setting standards and validating biomarkers and techniques that can hopefully be translated to clinical practice and disease-modifying therapeutic trials. We are also acutely aware that we aimed at describing the ocean, and as yet have only been able to provide a glass of water -- such is the complexity of the study of AD.

Abbreviations
=============

AD: Alzheimer's disease

ADNI: Alzheimer's Disease Neuroimaging Initiative

AIBL: Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging

ApoE: Apolipoprotein E

Aβ: Amyloid-beta

Aβ--: Low amyloid burden

Aβ+: High amyloid burden

CSF: Cerebrospinal fluid

E-ADNI: European Alzheimer's Disease Neuroimaging Initiative

FDG: Fluorodeoxyglucose

J-ADNI: Japanese Alzheimer's Disease Neuroimaging Initiative

MCI: Mild cognitive impairment

MRI: Magnetic resonance imaging

NA-ADNI: North American Alzheimer's Disease Neuroimaging Initiative

PET: Positron emission tomography

PiB: Pittsburgh Compound B

WW-ADNI: World Wide Alzheimer's Disease Neuroimaging Initiative

Competing interests
===================

As leaders for the respective ADNI consortia, SYK, CRC and TI received funds from governmental institutions and private pharmaceutical companies along with private nonprofit philanthropic organizations. The funding sources had no input in the design or writing of the review. VLV declares that he has no competing interests.

Authors' contributions
======================

VLV and TI participated in the design and writing of this review, and drafting of the manuscript. All authors were responsible for critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.
